Mindray Medical International Limited (NYSE: MR) reported earnings on Feb. 27. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Mindray Medical International Limited beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share grew.

Margins dropped across the board.

Revenue details
Mindray Medical International Limited logged revenue of $264.1 million. The eight analysts polled by S&P Capital IQ expected revenue of $248.1 million on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $211.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.44. The eight earnings estimates compiled by S&P Capital IQ predicted $0.44 per share on the same basis. GAAP EPS of $0.40 for Q4 were 14% higher than the prior-year quarter's $0.35 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 54.2%, 50 basis points worse than the prior-year quarter. Operating margin was 18.1%, 10 basis points worse than the prior-year quarter. Net margin was 17.7%, 180 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $210.6 million. On the bottom line, the average EPS estimate is $0.37.

Next year's average estimate for revenue is $1.03 billion. The average EPS estimate is $1.76.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,380 members out of 1,414 rating the stock outperform, and 34 members rating it underperform. Among 359 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 346 give Mindray Medical International Limited a green thumbs-up, and 13 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International Limited is outperform, with an average price target of $30.75.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Mindray Medical International Limited performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.